Early heart screening and treatment for sickle cell disease
Treatments studied
Part of Blood & lymphatic, Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This trial tests early screening and treatment to prevent heart problems in people with sickle cell disease. It focuses on those with high iron levels or heart symptoms, using regular heart imaging to monitor and treat complications early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have sickle cell disease (any type).
- You need to have either high iron levels in your blood (ferritin ≥400 ng/mL) or heart symptoms like shortness of breath or leg swelling.
- You must be willing to have regular heart tests (echocardiogram, ECG, heart MRI).
- You should be in good enough overall health to do daily activities (ECOG score 0-1).
- You cannot have known heart failure, unstable angina, or uncontrolled heart rhythm problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a stem cell transplant from a half-matched donor using a strong conditioning regimen and a drug called defibrotide to protect organs. It aims to cure sickle cell disease in patients who have had serious complications like stroke, chest syndrome, or frequent pain episodes.
This trial tests a new treatment called CS-206 for adolescents with severe sickle cell disease. It aims to see if this treatment can help by making stem cell transplants safer and more effective for people who have not done well with standard care.
This trial tests an investigational drug called DISC-3405 in people with sickle cell disease (SCD) to see if it is safe and how it affects your body. It may be an option if you have certain SCD complications or lab results.
This trial tests CS-206, an experimental therapy for people with sickle cell disease. It aims to reduce severe complications like pain crises, acute chest syndrome, strokes, and other serious events. You may qualify if you have a specific genetic type of sickle cell disease and have experienced complications despite standard treatments.
This trial tests a “biochip” device using samples from people with sickle cell disease. If it works, it may help doctors study sickle cell biology more accurately using patient samples.
This Phase 1 study tests whether nicotinamide, oral tetrahydrouridine, and decitabine can help people with high-risk sickle cell disease. It is mainly a safety-and-dosing study, but it also looks for signs the medicines may improve disease-related problems.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.